The Ebola virus VP35 protein is a suppressor of RNA silencing.

PubWeight™: 2.48‹?› | Rank: Top 2%

🔗 View Article (PMC 1894824)

Published in PLoS Pathog on June 01, 2007

Authors

Joost Haasnoot1, Walter de Vries, Ernst-Jan Geutjes, Marcel Prins, Peter de Haan, Ben Berkhout

Author Affiliations

1: Laboratory of Experimental Virology, Department of Medical Microbiology, Center of Infection and Immunity Amsterdam, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands.

Articles citing this

(truncated to the top 100)

The role of RNAi and microRNAs in animal virus replication and antiviral immunity. Genes Dev (2009) 3.30

RNA interference functions as an antiviral immunity mechanism in mammals. Science (2013) 2.77

Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis (2010) 2.24

Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat Struct Mol Biol (2010) 2.01

Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome. Cell Host Microbe (2013) 1.97

Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus. J Virol (2008) 1.96

Evasion of interferon responses by Ebola and Marburg viruses. J Interferon Cytokine Res (2009) 1.91

Human cellular restriction factors that target HIV-1 replication. BMC Med (2009) 1.86

Cellular microRNAs inhibit replication of the H1N1 influenza A virus in infected cells. J Virol (2010) 1.80

Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs. J Virol (2010) 1.72

Structure of the Ebola VP35 interferon inhibitory domain. Proc Natl Acad Sci U S A (2009) 1.71

Pyrosequencing of small non-coding RNAs in HIV-1 infected cells: evidence for the processing of a viral-cellular double-stranded RNA hybrid. Nucleic Acids Res (2009) 1.69

Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein. J Virol (2008) 1.65

The roles of microRNAs in mammalian virus infection. Biochim Biophys Acta (2008) 1.64

Noncoding flavivirus RNA displays RNA interference suppressor activity in insect and Mammalian cells. J Virol (2012) 1.58

Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression. Proc Natl Acad Sci U S A (2009) 1.48

Reciprocal inhibition between intracellular antiviral signaling and the RNAi machinery in mammalian cells. Cell Host Microbe (2013) 1.45

Suppression of HIV-1 replication by microRNA effectors. Retrovirology (2009) 1.44

Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA. Nat Microbiol (2016) 1.40

HIV-1 Tat RNA silencing suppressor activity is conserved across kingdoms and counteracts translational repression of HIV-1. Proc Natl Acad Sci U S A (2009) 1.39

Functions of the cytoplasmic RNA sensors RIG-I and MDA-5: key regulators of innate immunity. Pharmacol Ther (2009) 1.37

HIV-1 TAR miRNA protects against apoptosis by altering cellular gene expression. Retrovirology (2009) 1.35

Deep sequencing of virus-infected cells reveals HIV-encoded small RNAs. Nucleic Acids Res (2011) 1.32

Mechanisms employed by retroviruses to exploit host factors for translational control of a complicated proteome. Retrovirology (2009) 1.29

Ebolavirus proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway. J Virol (2011) 1.28

MicroRNAs and human retroviruses. Biochim Biophys Acta (2011) 1.23

Role of RNA interference (RNAi) in dengue virus replication and identification of NS4B as an RNAi suppressor. J Virol (2013) 1.21

Human microRNA hsa-miR-296-5p suppresses enterovirus 71 replication by targeting the viral genome. J Virol (2013) 1.18

Structural basis for Marburg virus VP35-mediated immune evasion mechanisms. Proc Natl Acad Sci U S A (2012) 1.18

Quantitative analysis of particles, genomes and infectious particles in supernatants of haemorrhagic fever virus cell cultures. Virol J (2011) 1.16

Herpes simplex virus 1 tegument protein US11 downmodulates the RLR signaling pathway via direct interaction with RIG-I and MDA-5. J Virol (2012) 1.14

The NS3 protein of rice hoja blanca virus complements the RNAi suppressor function of HIV-1 Tat. EMBO Rep (2009) 1.13

MicroRNAs and HIV-1: complex interactions. J Biol Chem (2012) 1.13

Small non-coding RNAs, mammalian cells, and viruses: regulatory interactions? Retrovirology (2007) 1.12

The Mammalian response to virus infection is independent of small RNA silencing. Cell Rep (2014) 1.12

Filoviral immune evasion mechanisms. Viruses (2011) 1.10

Adenovirus VA RNA-derived miRNAs target cellular genes involved in cell growth, gene expression and DNA repair. Nucleic Acids Res (2009) 1.08

Genome-wide screening using RNA interference to study host factors in viral replication and pathogenesis. Exp Biol Med (Maywood) (2011) 1.07

Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function. J Virol (2010) 1.07

Camouflage and misdirection: the full-on assault of ebola virus disease. Cell (2014) 1.07

Host restriction factors in retroviral infection: promises in virus-host interaction. Retrovirology (2012) 1.05

Structural and functional characterization of Reston Ebola virus VP35 interferon inhibitory domain. J Mol Biol (2010) 1.04

RNAi in the regulation of mammalian viral infections. BMC Biol (2012) 1.04

Marburg virus VP35 can both fully coat the backbone and cap the ends of dsRNA for interferon antagonism. PLoS Pathog (2012) 1.03

microRNAs in viral oncogenesis. Retrovirology (2007) 1.03

Ebolavirus VP35 is a multifunctional virulence factor. Virulence (2010) 1.02

Tat RNA silencing suppressor activity contributes to perturbation of lymphocyte miRNA by HIV-1. Retrovirology (2011) 0.99

CDK13, a new potential human immunodeficiency virus type 1 inhibitory factor regulating viral mRNA splicing. J Virol (2008) 0.99

In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity. J Mol Biol (2014) 0.96

Small RNA-mediated regulation of host-pathogen interactions. Virulence (2013) 0.96

Regulation of microRNA biogenesis and turnover by animals and their viruses. Cell Mol Life Sci (2013) 0.95

The extent of sequence complementarity correlates with the potency of cellular miRNA-mediated restriction of HIV-1. Nucleic Acids Res (2012) 0.94

Antiviral RNAi: translating science towards therapeutic success. Pharm Res (2011) 0.94

The ebolavirus VP24 interferon antagonist: know your enemy. Virulence (2012) 0.94

The HIV-1 protein Vpr targets the endoribonuclease Dicer for proteasomal degradation to boost macrophage infection. Virology (2013) 0.93

Development of RNA aptamers targeting Ebola virus VP35. Biochemistry (2013) 0.93

The VP35 protein of Ebola virus impairs dendritic cell maturation induced by virus and lipopolysaccharide. J Gen Virol (2009) 0.92

Titers of lentiviral vectors encoding shRNAs and miRNAs are reduced by different mechanisms that require distinct repair strategies. RNA (2010) 0.92

The A-rich RNA sequences of HIV-1 pol are important for the synthesis of viral cDNA. Nucleic Acids Res (2008) 0.92

Ebola virion attachment and entry into human macrophages profoundly effects early cellular gene expression. PLoS Negl Trop Dis (2011) 0.92

Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak. Clin Microbiol Rev (2015) 0.92

Construction of a doxycycline-dependent simian immunodeficiency virus reveals a nontranscriptional function of tat in viral replication. J Virol (2007) 0.92

Insights into cellular factors that regulate HIV-1 replication in human cells. Biochemistry (2011) 0.92

A re-examination of global suppression of RNA interference by HIV-1. PLoS One (2011) 0.92

DRBP76 associates with Ebola virus VP35 and suppresses viral polymerase function. J Infect Dis (2011) 0.91

The HIV-1 Tat protein has a versatile role in activating viral transcription. J Virol (2011) 0.91

Ebolavirus VP35 coats the backbone of double-stranded RNA for interferon antagonism. J Virol (2013) 0.90

MicroRNAs and their potential involvement in HIV infection. Trends Pharmacol Sci (2011) 0.90

The importance of the NP: VP35 ratio in Ebola virus nucleocapsid formation. J Infect Dis (2011) 0.90

Different Temporal Effects of Ebola Virus VP35 and VP24 Proteins on Global Gene Expression in Human Dendritic Cells. J Virol (2015) 0.90

Herpes simplex virus type 1 suppresses RNA-induced gene silencing in mammalian cells. J Virol (2009) 0.89

Rotavirus nonstructural protein 1 antagonizes innate immune response by interacting with retinoic acid inducible gene I. Virol J (2011) 0.89

The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals. Virology (2013) 0.89

The VP3 factor from viruses of Birnaviridae family suppresses RNA silencing by binding both long and small RNA duplexes. PLoS One (2012) 0.88

Protease activity, self interaction, and small interfering RNA binding of the silencing suppressor p1b from cucumber vein yellowing ipomovirus. J Virol (2007) 0.87

Hiding the evidence: two strategies for innate immune evasion by hemorrhagic fever viruses. Curr Opin Virol (2012) 0.87

Interfering RNA and HIV: reciprocal interferences. PLoS Pathog (2008) 0.87

RNAi-mediated inhibition of HIV-1 by targeting partially complementary viral sequences. Nucleic Acids Res (2009) 0.86

The 7a accessory protein of severe acute respiratory syndrome coronavirus acts as an RNA silencing suppressor. J Virol (2010) 0.86

Characterization of the RNA silencing suppression activity of the Ebola virus VP35 protein in plants and mammalian cells. J Virol (2012) 0.84

The Nucleocapsid Protein of Coronaviruses Acts as a Viral Suppressor of RNA Silencing in Mammalian Cells. J Virol (2015) 0.83

Innate immune evasion by filoviruses. Virology (2015) 0.82

Induction and suppression of antiviral RNA interference by influenza A virus in mammalian cells. Nat Microbiol (2016) 0.81

Antiviral RNA interference in animals: piecing together the evidence. Nat Struct Mol Biol (2013) 0.81

Localization and sub-cellular shuttling of HTLV-1 tax with the miRNA machinery. PLoS One (2012) 0.81

The Emerging Role of miRNAs in HTLV-1 Infection and ATLL Pathogenesis. Viruses (2015) 0.80

Mammalian MicroRNAs: Post-Transcriptional Gene Regulation in RNA Virus Infection and Therapeutic Applications. Front Microbiol (2010) 0.80

Predictive and comparative analysis of Ebolavirus proteins. Cell Cycle (2015) 0.79

Mechanisms of innate immune evasion in re-emerging RNA viruses. Curr Opin Virol (2015) 0.78

A multifunctional protein encoded by turkey herpesvirus suppresses RNA silencing in Nicotiana benthamiana. J Virol (2011) 0.78

Tombusvirus P19 RNA silencing suppressor (RSS) activity in mammalian cells correlates with charged amino acids that contribute to direct RNA-binding. Cell Biosci (2012) 0.78

Structural implications into dsRNA binding and RNA silencing suppression by NS3 protein of Rice Hoja Blanca Tenuivirus. RNA (2011) 0.78

Evasion of the interferon-mediated antiviral response by filoviruses. Viruses (2010) 0.77

Virus meets RNAi. Symposium on antiviral applications of RNA interference. EMBO Rep (2008) 0.77

Deployment of the human immunodeficiency virus type 1 protein arsenal: combating the host to enhance viral transcription and providing targets for therapeutic development. J Gen Virol (2012) 0.77

The effect of murine cytomegalovirus IE-3 specific shRNA is dependent on intragenic target site due to multiple transcription initiation sites. Herpesviridae (2011) 0.76

Host factors that interact with the pestivirus N-terminal protease, Npro, are components of the ribonucleoprotein complex. J Virol (2014) 0.76

A Tale of Two RNAs during Viral Infection: How Viruses Antagonize mRNAs and Small Non-Coding RNAs in The Host Cell. Viruses (2016) 0.76

HIV-1 RRE RNA acts as an RNA silencing suppressor by competing with TRBP-bound siRNAs. RNA Biol (2015) 0.76

Human immunodeficiency virus Tat associates with a specific set of cellular RNAs. Retrovirology (2014) 0.76

Articles cited by this

How cells respond to interferons. Annu Rev Biochem (1998) 24.27

Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature (2006) 22.65

Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature (2005) 17.47

Plant pathogens and integrated defence responses to infection. Nature (2001) 14.67

Identification of virus-encoded microRNAs. Science (2004) 12.56

Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev (2002) 10.71

Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology (1998) 9.81

A cellular microRNA mediates antiviral defense in human cells. Science (2005) 8.48

Viruses and interferon: a fight for supremacy. Nat Rev Immunol (2002) 7.92

Hierarchical action and inhibition of plant Dicer-like proteins in antiviral defense. Science (2006) 6.33

Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell (1989) 6.28

Induction and suppression of RNA silencing by an animal virus. Science (2002) 6.28

RNA interference directs innate immunity against viruses in adult Drosophila. Science (2006) 5.74

The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A (2000) 5.46

Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science (2007) 5.07

Induction and suppression of RNA silencing: insights from viral infections. Nat Rev Genet (2005) 4.98

Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J Virol (2006) 4.88

L1 retrotransposition is suppressed by endogenously encoded small interfering RNAs in human cultured cells. Nat Struct Mol Biol (2006) 4.80

The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase. Proc Natl Acad Sci U S A (1992) 4.74

Adenovirus VAI RNA antagonizes the antiviral action of interferon by preventing activation of the interferon-induced eIF-2 alpha kinase. Cell (1986) 4.72

Essential function in vivo for Dicer-2 in host defense against RNA viruses in drosophila. Nat Immunol (2006) 4.69

Interferon action and apoptosis are defective in mice devoid of 2',5'-oligoadenylate-dependent RNase L. EMBO J (1997) 4.53

Binding of the influenza virus NS1 protein to double-stranded RNA inhibits the activation of the protein kinase that phosphorylates the elF-2 translation initiation factor. Virology (1995) 4.43

Transposon silencing in the Caenorhabditis elegans germ line by natural RNAi. Nature (2003) 4.09

Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing. Proc Natl Acad Sci U S A (2004) 3.85

Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol (2006) 3.84

Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing. Immunity (2005) 3.70

Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines. Proc Natl Acad Sci U S A (1988) 3.67

The primary function of RNA binding by the influenza A virus NS1 protein in infected cells: Inhibiting the 2'-5' oligo (A) synthetase/RNase L pathway. Proc Natl Acad Sci U S A (2006) 3.50

A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat Biotechnol (2006) 3.46

Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol (2004) 3.23

Small RNA binding is a common strategy to suppress RNA silencing by several viral suppressors. EMBO J (2006) 3.00

Influenza virus evades innate and adaptive immunity via the NS1 protein. J Virol (2006) 2.94

HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res (2005) 2.93

RNA interference is an antiviral defence mechanism in Caenorhabditis elegans. Nature (2005) 2.93

Adenovirus VA1 noncoding RNA can inhibit small interfering RNA and MicroRNA biogenesis. J Virol (2004) 2.77

Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of vaccinia virus. J Virol (2002) 2.37

A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus. Virology (2004) 2.37

Suppression of RNA interference by adenovirus virus-associated RNA. J Virol (2005) 2.29

Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis (2006) 2.19

An antiviral role for the RNA interference machinery in Caenorhabditis elegans. Proc Natl Acad Sci U S A (2005) 2.16

Is RNA interference involved in intrinsic antiviral immunity in mammals? Nat Immunol (2006) 2.02

Double-stranded RNA binding may be a general plant RNA viral strategy to suppress RNA silencing. J Virol (2006) 1.94

The influenza A virus NS1 protein binds small interfering RNAs and suppresses RNA silencing in plants. J Gen Virol (2004) 1.93

Strict control of human immunodeficiency virus type 1 replication by a genetic switch: Tet for Tat. J Virol (2001) 1.89

Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication. J Virol (2006) 1.78

Vaccinia virus E3L protein is an inhibitor of the interferon (i.f.n.)-induced 2-5A synthetase enzyme. Virology (1998) 1.73

VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother (2006) 1.63

The Tat protein of human immunodeficiency virus type 1 is a substrate and inhibitor of the interferon-induced, virally activated protein kinase, PKR. J Biol Chem (1997) 1.63

Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections. Proc Natl Acad Sci U S A (2004) 1.51

Determination of the minimal amount of Tat activity required for human immunodeficiency virus type 1 replication. Virology (1997) 1.39

Double-stranded RNA-binding proteins could suppress RNA interference-mediated antiviral defences. J Gen Virol (2003) 1.37

A potential role for RNA interference in controlling the activity of the human LINE-1 retrotransposon. Nucleic Acids Res (2005) 1.34

Hepatitis C virus core protein is a potent inhibitor of RNA silencing-based antiviral response. Gastroenterology (2006) 1.31

Human influenza virus NS1 protein enhances viral pathogenicity and acts as an RNA silencing suppressor in plants. J Gen Virol (2004) 1.26

The Tombusvirus-encoded P19: from irrelevance to elegance. Nat Rev Microbiol (2006) 1.22

RNA interference: its use as antiviral therapy. Handb Exp Pharmacol (2006) 0.99

Articles by these authors

Identification of a new human coronavirus. Nat Med (2004) 11.24

Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52

Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol (2002) 3.59

Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol (2004) 3.23

HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res (2005) 2.93

Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS (2004) 2.51

Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther (2006) 2.48

Suppression of RNA interference by adenovirus virus-associated RNA. J Virol (2005) 2.29

A novel pancoronavirus RT-PCR assay: frequent detection of human coronavirus NL63 in children hospitalized with respiratory tract infections in Belgium. BMC Infect Dis (2005) 2.28

Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A (2005) 2.21

Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther (2008) 2.14

RNA interference against viruses: strike and counterstrike. Nat Biotechnol (2007) 2.14

Chemical probes for the rapid detection of Fatty-acylated proteins in Mammalian cells. J Am Chem Soc (2007) 2.10

Viral evolution as a tool to improve the tetracycline-regulated gene expression system. J Biol Chem (2004) 2.06

In HIV-1 pathogenesis the die is cast during primary infection. AIDS (2007) 2.04

Croup is associated with the novel coronavirus NL63. PLoS Med (2005) 2.03

Detection of new viruses by VIDISCA. Virus discovery based on cDNA-amplified fragment length polymorphism. Methods Mol Biol (2008) 1.95

The influenza A virus NS1 protein binds small interfering RNAs and suppresses RNA silencing in plants. J Gen Virol (2004) 1.93

Retroviral superinfection resistance. Retrovirology (2005) 1.82

A novel long distance base-pairing interaction in human immunodeficiency virus type 1 RNA occludes the Gag start codon. J Biol Chem (2002) 1.81

Differential transmission of human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. J Virol (2002) 1.78

Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies. J Virol (2002) 1.75

The leader of human immunodeficiency virus type 1 genomic RNA harbors an internal ribosome entry segment that is active during the G2/M phase of the cell cycle. J Virol (2003) 1.71

Inhibition of virus replication by RNA interference. J Biomed Sci (2003) 1.70

Sequence-based physical mapping of complex genomes by whole genome profiling. Genome Res (2011) 1.69

Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res (2008) 1.65

Factor correction as a tool to eliminate between-session variation in replicate experiments: application to molecular biology and retrovirology. Retrovirology (2006) 1.64

Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol (2004) 1.64

Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J Clin Microbiol (2008) 1.61

The novel human coronaviruses NL63 and HKU1. J Virol (2006) 1.59

Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol (2004) 1.53

Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol (2007) 1.52

Multiple secondary structure rearrangements during HIV-1 RNA dimerization. Biochemistry (2002) 1.50

Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted by RNA interference. J Virol (2007) 1.50

Microprocessor, Setx, Xrn2, and Rrp6 co-operate to induce premature termination of transcription by RNAPII. Cell (2012) 1.49

The tRNA primer activation signal in the human immunodeficiency virus type 1 genome is important for initiation and processive elongation of reverse transcription. J Virol (2002) 1.40

Mosaic structure of human coronavirus NL63, one thousand years of evolution. J Mol Biol (2006) 1.40

Proteomic studies reveal coordinated changes in T-cell expression patterns upon infection with human immunodeficiency virus type 1. J Virol (2008) 1.40

HIV-1 Tat RNA silencing suppressor activity is conserved across kingdoms and counteracts translational repression of HIV-1. Proc Natl Acad Sci U S A (2009) 1.39

Genome structure and transcriptional regulation of human coronavirus NL63. Virol J (2004) 1.39

Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology (2013) 1.37

Human coronavirus NL63, a new respiratory virus. FEMS Microbiol Rev (2006) 1.37

Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology (2010) 1.36

The HIV-1 leader RNA conformational switch regulates RNA dimerization but does not regulate mRNA translation. Biochemistry (2005) 1.36

Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner. J Virol (2004) 1.34

Lewis X component in human milk binds DC-SIGN and inhibits HIV-1 transfer to CD4+ T lymphocytes. J Clin Invest (2005) 1.34

Lack of detection of XMRV in seminal plasma from HIV-1 infected men in The Netherlands. PLoS One (2010) 1.34

Identification of conserved and novel microRNAs that are responsive to heat stress in Brassica rapa. J Exp Bot (2011) 1.33

Deep sequencing of virus-infected cells reveals HIV-encoded small RNAs. Nucleic Acids Res (2011) 1.32

A miRNA-tRNA mix-up: tRNA origin of proposed miRNA. RNA Biol (2010) 1.30

A riboswitch regulates RNA dimerization and packaging in human immunodeficiency virus type 1 virions. J Virol (2004) 1.30

Human parechovirus type 1, 3, 4, 5, and 6 detection in picornavirus cultures. J Clin Microbiol (2007) 1.28

A systematic analysis of the effect of target RNA structure on RNA interference. Nucleic Acids Res (2007) 1.27

Negative-strand tospoviruses and tenuiviruses carry a gene for a suppressor of gene silencing at analogous genomic positions. J Virol (2003) 1.26

Dimerization and template switching in the 5' untranslated region between various subtypes of human immunodeficiency virus type 1. J Virol (2003) 1.26

Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia. J Neurol (2005) 1.23

Comparison of single regulated lentiviral vectors with rtTA expression driven by an autoregulatory loop or a constitutive promoter. Nucleic Acids Res (2005) 1.23

Differential susceptibility of naïve, central memory and effector memory T cells to dendritic cell-mediated HIV-1 transmission. Retrovirology (2006) 1.23

The TAR hairpin of human immunodeficiency virus type 1 can be deleted when not required for Tat-mediated activation of transcription. J Virol (2007) 1.22

RNA structure modulates splicing efficiency at the human immunodeficiency virus type 1 major splice donor. J Virol (2007) 1.22

Selection of T1249-resistant human immunodeficiency virus type 1 variants. J Virol (2008) 1.21

Sialoadhesin (CD169) expression in CD14+ cells is upregulated early after HIV-1 infection and increases during disease progression. PLoS One (2007) 1.21

The virion-associated incoming HIV-1 RNA genome is not targeted by RNA interference. Retrovirology (2006) 1.20

Regulated HIV-2 RNA dimerization by means of alternative RNA conformations. Nucleic Acids Res (2002) 1.20

Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr (2008) 1.20

Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands. PLoS One (2009) 1.20

Cloning and characterization of the durable tomato mosaic virus resistance gene Tm-2(2) from Lycopersicon esculentum. Plant Mol Biol (2003) 1.20

Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J Gen Virol (2006) 1.19

Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN--gp120 interaction. J Virol (2005) 1.19

RNAi suppressors encoded by pathogenic human viruses. Int J Biochem Cell Biol (2008) 1.18

Combinatorial RNAi against HIV-1 using extended short hairpin RNAs. Mol Ther (2009) 1.18

Effects of random mutations in the human immunodeficiency virus type 1 transcriptional promoter on viral fitness in different host cell environments. J Virol (2006) 1.16

Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS One (2009) 1.16

HIV-1 latency in actively dividing human T cell lines. Retrovirology (2008) 1.16

Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J Infect Dis (2012) 1.13

The NS3 protein of rice hoja blanca virus complements the RNAi suppressor function of HIV-1 Tat. EMBO Rep (2009) 1.13

Inhibition of HIV-1 by fusion inhibitors. Curr Pharm Des (2010) 1.13

Probing alternative foldings of the HIV-1 leader RNA by antisense oligonucleotide scanning arrays. Nucleic Acids Res (2004) 1.12

The NS3 protein of Rice hoja blanca tenuivirus suppresses RNA silencing in plant and insect hosts by efficiently binding both siRNAs and miRNAs. RNA (2007) 1.12

Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. J Biol Chem (2009) 1.11

SHAPE-directed discovery of potent shRNA inhibitors of HIV-1. Mol Ther (2012) 1.11

The biased nucleotide composition of the HIV genome: a constant factor in a highly variable virus. Retrovirology (2012) 1.10

Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution. J Virol (2008) 1.10

The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. Retrovirology (2008) 1.10

Triple HIV-1 infection. N Engl J Med (2005) 1.09

A novel class of heat-responsive small RNAs derived from the chloroplast genome of Chinese cabbage (Brassica rapa). BMC Genomics (2011) 1.09

Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. J Virol (2011) 1.09

Survey of the temporal changes in HIV-1 replicative fitness in the Amsterdam Cohort. Virology (2007) 1.08

RNAi and cellular miRNAs in infections by mammalian viruses. Methods Mol Biol (2011) 1.08

Antibacterial and antiviral effects of milk proteins and derivatives thereof. Curr Pharm Des (2003) 1.08

Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob Agents Chemother (2006) 1.07

Inhibition of human immunodeficiency virus type 1 replication with artificial transcription factors targeting the highly conserved primer-binding site. J Virol (2006) 1.07

Dicer-independent processing of short hairpin RNAs. Nucleic Acids Res (2013) 1.06

RNA-seq pinpoints a Xanthomonas TAL-effector activated resistance gene in a large-crop genome. Proc Natl Acad Sci U S A (2012) 1.06

Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structure. AIDS Res Hum Retroviruses (2004) 1.06

Design of extended short hairpin RNAs for HIV-1 inhibition. Nucleic Acids Res (2007) 1.06

The HIV RNA setpoint theory revisited. Retrovirology (2007) 1.06

A novel approach for inhibition of HIV-1 by RNA interference: counteracting viral escape with a second generation of siRNAs. J RNAi Gene Silencing (2005) 1.06